Lipocine Inc.
LPCNDrugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How LPCN's past catalysts played out
LPCN 1154A
Depression, Postpartum
Oral testosterone undecanoate, LPCN 1021
Male Hypogonadism
LPCN 1021
Hypogonadism, Male
LPCN 1144 Formulation A
Nonalcoholic Steatohepatitis (NASH)
LPCN 1144
NASH - Nonalcoholic Steatohepatitis
LPCN 1148
Liver Cirrhosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
LPCN 1154A | Phase 3 | Depression, Postpartum | - | - |
Oral testosterone undecanoate, LPCN 1021 | Phase 3 | Male Hypogonadism | - | - |
LPCN 1021 | Phase 3 | Hypogonadism, Male | - | - |
LPCN 1144 Formulation A | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
LPCN 1144 | Phase 2 | NASH - Nonalcoholic Steatohepatitis | - | - |
LPCN 1148 | Phase 2 | Liver Cirrhosis | - | - |
Frequently asked questions
What is in Lipocine Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Lipocine Inc.'s (LPCN) pipeline across Phase 3, Phase 2. Its lead program is LPCN 1154A (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lipocine Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Lipocine Inc. (LPCN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LPCN biotech catalysts?→
Add LPCN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lipocine Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.